Pall Corporation Magnifies Focus on Instrumentation with Expansion of Menlo Park Facility

PORT WASHINGTON, N.Y.--(BUSINESS WIRE)--Pall Corporation (NYSE:PLL), a global leader in filtration, separation and purification, today announced that it has expanded its Menlo Park, California facility, the site of its ForteBio® operations, to create a Center of Excellence (COE) for Instrumentation. The expanded COE, located in the heart of the Silicon Valley/Bay area, occupies more than 42,000 sq. feet on two floors, which is nearly double the size of the original facility. The multi-disciplinary center handles a broad range of functions from instrument and consumable reagent manufacturing to product development. Acquired by Pall in 2012, ForteBio is a division of Pall Life Sciences.

“Process instrumentation represents an important growth market for Pall”

“Process instrumentation represents an important growth market for Pall,” said Yves Baratelli, president, Pall Life Sciences. “By creating a center that focuses on instrumentation and process monitoring system design and development, we are now better positioned to meet the evolving needs of our research and drug development customers worldwide. The location of the new COE also will allow us to capitalize on emerging opportunities in strategic local areas such as the Silicon Valley region.”

To further demonstrate Pall’s commitment to meeting the widening range of analytical, testing and monitoring needs of its customers, Pall doubled its Menlo Park facility’s engineering staff and now operates its Global Instrumentation Field Service Group from the site. Having the field service, design engineering and manufacturing teams housed at the same facility will enable Pall to build greater serviceability into its solutions. The facility also offers customer training.

ForteBio’s flagship Octet® instrumentation platform and related consumable reagents, as well as the revolutionary smaller scale BLItz™ system, continue to be manufactured at the Menlo Park facility. The BLItz system enables scientists to easily and cost-effectively conduct label-free analyses of proteins using small sample volumes right at their lab bench.

Additional activities being performed at the site include manufacturing of the Pall® Micro-24 MicroReactor process development system for cell culture and leading-edge software development related to Pall’s GeneDisc® pathogen detection platform.

While the current focus of the COE is on life sciences applications, Pall plans to make the COE an authority on all Pall instrumentation design and development opportunities.

About Pall Life Sciences

Pall Life Sciences provides cutting-edge products and services to meet the demanding needs of customers discovering, developing and producing biotech drugs, vaccines and classic pharmaceuticals. Pall’s membranes and membrane devices optimize detection and sample preparation in the drug research, clinical diagnostics, genomics, and proteomics markets. Pall is a leading provider of separation systems and single-use filtration and purification technologies to pharmaceutical and biotechnology companies to support faster development of new drugs and vaccines that are safer and require less energy and water to produce. Pall technologies are also used in clinical institutions and the food and beverage industries.

About Pall Corporation
Pall Corporation (NYSE:PLL) is a filtration, separation and purification leader providing solutions to meet the critical fluid management needs of customers across the broad spectrum of life sciences and industry. Pall works with customers to advance health, safety and environmentally responsible technologies. The company’s engineered products enable process and product innovation and minimize emissions and waste. Pall Corporation is an S&P 500 company serving customers worldwide. Pall has been named a “top green company” by Newsweek magazine. To see how Pall is helping enable a greener, safer, more sustainable future, follow us on Twitter @PallCorporation or visit www.pall.com/green.